Names Board of Directors
SAN DIEGO, Jan. 31 /PRNewswire/ -- Sonexa Therapeutics, Inc., a
clinical-stage biopharmaceutical company developing therapeutics for the
treatment of Alzheimer's disease, announced today that it has raised $30
million in a Series A round of financing. The financing was led by Domain
Associates, L.L.C., Scale Venture Partners and Alta Partners. Additional
investors included AgeChem Venture Fund, and MC Life Science Ventures.
Sonexa also announced the appointment of its Board of Directors. Sonexa
founding CEO Eckard Weber, M.D., will serve as Chairman. Weber, a Partner
with Domain Associates, is a founding CEO of more than a dozen
biopharmaceutical companies. Additional Directors include Kim Puloma
Kamdar, Ph.D., of Domain Associates, Lou Bock, a Managing Director with
Scale Venture Partners, and Robert Alexander, Ph.D., with Alta Partners.
The management team includes president and CMO Sharon Rogers, Ph.D., who
played a leading role in developing Aricept, the top-selling Alzheimer's
medication.
Proceeds from the financing will be used to fund the licensing and
development of a novel drug being tested as a therapeutic to treat
Alzheimer's disease. Sonexa has licensed worldwide, exclusive rights
(except for Japan and certain Asian countries) to the compound from a
Japanese pharmaceutical company. Human trials in the US are scheduled to
begin February '08.
About Domain Associates
Founded in 1985, Domain Associates, L.L.C. is a venture capital firm
with an exclusive focus on life sciences. With $2.1 billion of capital
under management, Domain is headquartered in Princeton, NJ with a second
office in San Diego, CA. Domain's three major investment segments are
pharmaceuticals, specialty pharmaceuticals, and medical devices, while
additional areas of interest include biomaterials, bioinstrumentation, and
diagnostics. The Partners of Domain have a total of close to 200
person-years of experience among them in the healthcare/venture capital
industries and have been involved in the formation and growth of more than
190 life-sciences companies. For more information, visit
http://www.domainvc.com.
About Scale Venture Partners
Based in Foster City, California, the ScaleVP team is a long-standing
partnership with a consistent, top quartile track record of returns. Scale
Venture Partners' insight-driven investment strategy, extensive operating
networks and go-to-market expertise help identify and build winning
portfolio companies in technology and healthcare markets. The ScaleVP
team's proven skill-set and active approach provides entrepreneurs a
competitive advantage for growth and category leadership. Representative
portfolio companies include Alimera Sciences, Discera, Frontbridge, Glu
Mobile, mBlox, Monolithic Power Systems, National Healing, NComputing,
Omniture, Orexigen, ScanSafe, Somaxon, Vantage Media, Waterfront Media,
Xceive and Zogenix. For more information, visit http://www.scalevp.com.
About Alta Partners
Alta Partners is a San Francisco based venture capital firm focused on
life sciences investing. Founded in 1996, the firm currently manages over
$2 billion in committed capital through eight venture fund programs. Alta
invests in life sciences companies across the development continuum, from
company formation to later-stage venture opportunities, and has funded over
110 companies in the sector to date. For more information, please visit
http://www.altapartners.com.
Media Contact:
For Sonexa:
Eckard Weber, MD
CEO
Sonexa Therapeutics, Inc.
weber@domainvc.com
858-480-2400
For Scale Venture Partners:
Carol Sacks
Tenor Communications
carol@tenorcom.com
650.520.8261
SOURCE Sonexa Therapeutics, Inc.
 back to top
Related links:
http://www.domainvc.com
http://www.scalevp.com http://www.altapartners.com
CONTACT:
Eckard Weber, MD, CEO of Sonexa Therapeutics,
Inc., +1-858-480-2400, weber@domainvc.com; or Carol Sacks of
Tenor Communications, +1-650-520-8261, carol@tenorcom.com, for
Scale Venture Partners
|
